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Abstract
In this paper we described the first Polish patient with ferroportin disease. Hereditary haemochromatosis (HH) is a condition 
associated with universal iron overload, and it is divided into four types, according to the Online Mendelian Inheritance in Man 
(OMIM) database. Ferroportin disease represented a rare type of HH, with autosomal dominant trait of inheritance. In our patient 
we detected a novel mutation in the ferroportin gene, with non-classical phenotype.
Introduction
Haemochromatosis (HH) is a well-defined condition 
characterised by normal iron-driven erythropoiesis and 
the toxic accumulation of iron in parenchymal cells of 
the liver, heart, and endocrine glands. It can be caused 
by mutations that affect any of the proteins that limit 
the entry of iron into the blood [1]. The most common 
form of HH is associated with HFE gene mutation and 
called HFE-hemochromatosis. The other form of HH 
are named non-HFE. Non-HFE haemochromatosis syn-
dromes define a subgroup of hereditary iron loading 
disorders that share the autosomal recessive trait, the 
pathogenic basis (i.e. lack of hepcidin synthesis or ac-
tivity), and key clinical features with classic HFE-haemo-
chromatosis. They are caused by pathogenic mutations 
in other genes, such as transferrin receptor 2 (TFR2), 
hepcidin (HAMP), haemojuvelin (HJV), and ferroportin 
(FPN), and, unlike HFE-haemochromatosis, they are not 
restricted to Caucasians. Ferroportin disease, the most 
common non-HFE hereditary iron-loading disorder, is 
caused by a loss of iron export function of ferroportin 
(FPN) resulting in early and preferential iron accumula-
tion in Kupffer cells and macrophages with high ferritin 
levels and low-to-normal transferrin saturation. This au-
tosomal dominant disorder usually has milder expres-
sivity than haemochromatosis [2].
We report a 53-year-old patient with a hepcidin-re-
sistant form of hereditary haemochromatosis (HH) – 
ferroportin disease. Unlike the most common HFE-relat-
ed form of hereditary haemochromatosis, this condition 
has an autosomal dominant trait of transmission. Our 
patient was found to be a carrier of a novel Y64H mu-
tation in exon 3 of the SCL40A1 gene. In the described 
subject the disease was associated with a non-classical 
phenotype manifesting itself with more severe hepatic 
iron overload and more advanced liver fibrosis. 
Case report
A 53-year-old male patient was admitted to the 
Liver Unit of the Pomeranian Medical University with 
clinical suspicion of liver cirrhosis. He complained of 
generalized weakness, fatigue, and recurrent epigastric 
pain. Physical examination revealed no abnormalities. 
His blood analysis showed hypercholesterolaemia and 
impaired glucose tolerance. Liver biochemistry showed 
mild hypertransaminasaemia with alanine transaminase 
(ALT) > aspartate aminotransferase (AST) and slight el-
evation of alkaline phosphatase (ALP). Other laboratory 
tests demonstrated high ferritin of > 6000 ng/dl (refer-
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ence value 28–365 ng/ml) and high transferrin satura-
tion of up to 98%, with normal iron of 150 mg/dl (33– 
193 mg/dl) and low UIBC. H63D and C282Y HFE gene 
mutations were excluded. Liver biopsy revealed features 
of advanced fibrosis fulfilling histological criteria of cir-
rhosis and deposits of haemosiderin in hepatocytes, 
macrophages, and ductal epithelium (Figure 1). Despite 
putting the patient on a regular phlebotomy protocol his 
transferrin saturation and ferritin levels did not show 
significant improvement over the period of 2 years with 
marked iron overload of parenchymal organs on mag-
netic resonance imaging (MRI) scans (Figure 2). However, 
the patient has remained clinically well with Child-Pugh 
score A and no episodes of decompensation of his liver 
function. Mutations of the TfR2 gene were subsequently 
excluded, and lastly the Y64H mutation of the ferropor-
tin gene was found – a heterozygote exon 3 ferroportin 
mutation c.190T>C (p. Y64H or Tyr64His).
Discussion
Haemochromatosis is a hereditary iron overload dis-
order resulting from dysregulation of iron homeostasis 
[1]. The disease is usually transmitted as an autosomal 
recessive trait and is mainly due to mutations of the 
HFE gene. The minority of cases are associated with 
TfR2 gene mutations and severe, early onset forms are 
associated with mutations of the haemojuvelin (HJV) 
and hepcidin (HAMP) genes. More recently, an autoso-
mal dominant form of hereditary haemochromatosis 
(HH) has been described (ferroportin disease) due to 
mutations in the ferroportin 1 gene (also known as sol-
ute carrier family 40, member A1, or SCL40A1) [3].
The ferroportin gene, SCL40A1, encodes a 62.5 kDa 
protein which localises to the cell surface and is pos-
tulated to contain 12 transmembrane domains. Ferro-
portin is the only known iron efflux transporter and is 
regulated by hepcidin, the key regulator of iron homeo-
stasis. Long-term iron loading resulting from ferroportin 
disease has a broad spectrum of outcomes depending 
on the disease-causing mutations. Liver damage, in-
cluding fibrosis and/or cirrhosis, can occur. The clinical 
presentation and natural course of ferroportin disease 
has been documented in individual case reports and 
small case series [3]. A recent meta-analysis on individ-
uals with SLC40A1 gene mutations showed that, in con-
trast to HFE haemochromatosis, ferroportin disease has 
a high penetrance, is genetically heterogeneous, and is 
rarely associated with fibrosis [4]. Hyperferritinaemia, 
a normal to low transferrin saturation, and Kupffer cell 
iron storage, presenting as hepatic and spleen iron over-
load, are considered characteristic features of classical 
ferroportin disease. Increased transferrin saturation and 
hepatocellular iron overload, in addition to hyperferriti-
naemia and macrophage iron loading, are both consid-
ered characteristic for the non-classical phenotype [3]. 
A genotype-phenotype correlation was suggested to 
explain the heterogeneity of ferroportin disease where 
most mutations (e.g. A77D, D157G, V162del, N174I, 
Q182H, Q248H, and G323V) are associated with classical 
ferroportin disease. In this classical form, macrophage 
iron overload results from cellular iron export deficiency, 
i.e. loss of ferroportin function. Distinct mutations (e.g. 
N144H, Y64N, C326Y/S, S338R, and Y501C) have been 
found in patients who presented with the non-classical 
phenotype associated with a higher risk of fibrosis and 
a more severe overload of hepatic iron, as in the case 
mentioned above [4, 5].
Rivard et al., in 2003, reported a Y64N mutation-as-
sociated ferroportin disease in a large pedigree [6]. 
However, this amino acid change would imply a T>A nu-
cleotide change at the cDNA level, and not the T>C 
change described in their report [6]. In fact, the T>C 
nucleotide change at position 190 of the cDNA (codon 
TAC, coding for tyrosine 64, Y) results in CAC, coding 
for histidine, H, not asparagine, N. In the Human Gene 
Figure 1. Liver biopsy (dyeing aniline blue, 100×)
Figure 2. Magnetic resonance imaging scan of 
the iron overloaded liver
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Mutation Database (http://www.hgmd.org/) the ferro-
portin mutation described by Rivard et al. is reported as 
a T>A change (Y64N). 
The FNP gene mutation in our case has a different AA 
change, but of the same amino acid position described 
in the French-Canadian family [6]. The mutation is locat-
ed in the first transmembrane domain of the ferropor-
tin 1 protein, suggesting that this part of the ferroportin 
protein may act as a functional binding site for proteins, 
such as apotransferrin, ceruloplasmin, or hephaestin, 
which is important for the export of iron from the cell 
[6]. In a number of in vitro studies it has been shown 
that the Y64N mutation is associated with resistance 
to hepcidin regulation. Hepcidin is the main circulating 
inhibitor of iron flux from enterocytes, hepatocytes, 
macrophages, and placental cells into the bloodstream, 
producing this effect by binding to ferroportin. Hepcidin, 
secreted by hepatocytes into the circulation in response 
to pro-inflammatory cytokines, hepatocellular iron load-
ing, and endoplasmic reticulum stress, directly interacts 
with ferroportin and induces its internalisation and deg-
radation. Ferroportin inactivation is mediated by the 
hepcidin, and lack of binding site for this protein, due 
to Y64H mutation, may result in intracellular retention 
of the iron export pump, and non-classical form of the 
disease. In fact, our patient presented with increased 
transferrin saturation, massive parenchymal iron over-
load in the liver, with iron-spared Kupffer cells, and no 
iron accumulation in the spleen, as documented by MRI 
– a phenotypic expressivity identical to classic haemo-
chromatosis. Therefore, Y64H mutation of the FPN gene 
belongs to haemochromatosis resistant to hepcidin, and 
this report is the first Polish ferroportin-related haemo-
chromatosis case of non-classical phenotype.
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